thymol has been researched along with Parkinson Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Azizi, Z; Farhadi, M; Manouchehrabadi, M; Nourmohammadi, S; Torkaman-Boutorabi, A; Yousefi, S | 1 |
| Ansari, SA; Azimullah, S; Javed, H; Meeran, MFN; Ojha, S | 1 |
2 other study(ies) available for thymol and Parkinson Disease
| Article | Year |
|---|---|
Thymol protects against 6-hydroxydopamine-induced neurotoxicity in in vivo and in vitro model of Parkinson's disease via inhibiting oxidative stress.
Topics: Animals; Humans; Neuroprotective Agents; Oxidative Stress; Oxidopamine; Parkinson Disease; Rats; Thymol | 2022 |
Neuroprotective Effects of Thymol, a Dietary Monoterpene Against Dopaminergic Neurodegeneration in Rotenone-Induced Rat Model of Parkinson's Disease.
Topics: Animals; Catalase; Cyclooxygenase 2; Cytokines; Diet; Disease Models, Animal; Dopaminergic Neurons; Glutathione; Inflammation Mediators; Lipid Peroxidation; Male; Malondialdehyde; Neostriatum; Nerve Degeneration; Neuroglia; Neuroprotective Agents; Nitric Oxide Synthase Type II; Parkinson Disease; Rats, Wistar; Rotenone; Substantia Nigra; Superoxide Dismutase; Thymol; Tyrosine 3-Monooxygenase | 2019 |